Document:

Exhibit 10.1

 

CONSULTING AGREEMENT

 

This Consulting Agreement (the “Agreement”)
is made as of November 10, 2018 (the “Effective Date”), by and between
MyDx, Inc., a Nevada corporation (the “Company”), and Mr. Cannabis, Inc.,
a California corporation (“Consultant”).

 

1. Consulting
Relationship. During the term of this Agreement, Consultant will provide consulting services to the Company as described
on Exhibit A hereto (the “Services”).
Consultant represents that Consultant has the qualifications, the experience and the ability to properly perform the Services.
Consultant shall use Consultant’s best efforts to perform the Services such that the results are satisfactory to the Company.

 

2. Fees.
As consideration for the Services to be provided by Consultant and other obligations, the Company shall pay to Consultant the amounts
specified in Exhibit B hereto at the times specified therein.

 

3. Expenses.
Consultant shall not be authorized to incur on behalf of the Company any expenses and will be responsible for all expenses incurred
while performing the Services unless otherwise agreed to by the Company’s Officers, which consent shall be evidenced in writing
for any expenses in excess of $50. As a condition to receipt of reimbursement, Consultant shall be required to submit to the Company
reasonable evidence that the amount involved was both reasonable and necessary to the Services provided under this Agreement.

 

4. Term and Termination.
Consultant shall serve as a consultant to the Company for a period commencing on the Effective Date and terminating on the 36-month
anniversary of the Effective Date (the “Term”). It’s agreed to by all parties that neither party can terminate
this agreement within the first six months 6 months from the date of execution. Notwithstanding the above or anything to the contrary
in this Agreement, either party may terminate this Agreement, with or without cause, at any time after the 6 month anniversary
of this agreement upon providing 90-day’s prior written notice to the other party. In the event of such termination, either
party shall pay any amounts due to the other party as set forth on Exhibit B prior to the date of termination, if any. Once
the consultant has successfully completed any of the accelerated vesting milestones number 1, 2, 3, 4, 5, or 6 referenced in Exhibit
B, both parties agree that the prior period of written notice for termination for both consultant and company will increase from
90 days to 180 days written notice, so that either party may terminate this Agreement, with or without cause, upon providing 180-day’s
prior written notice to the other party.

 

5. Independent
Contractor. Although those persons hired by Consultant to fulfill certain roles with the Company may be deemed employees,
the relationship between Consultant itself with the Company will be that of an independent contractor and not that of an employee.

 

6. Method
of Provision of Services. Consultant shall be solely responsible for determining the method, details and means of performing
the Services. Consultant may, at Consultant’s own expense, employ or engage the services of such employees, subcontractors,
partners or agents, as Consultant deems necessary to perform the Services.

 

(a) No Authority to Bind Company.
Consultant acknowledges and agrees that Consultant has no authority to enter into contracts that bind the Company or create
obligations on the part of the Company without the prior written authorization of the Company.

 

     

     

    

 

(b) No Benefits.
Consultant acknowledges and agrees that Consultant shall not be eligible for any Company employee benefits and, to the extent Consultant
otherwise would be eligible for any Company employee benefits but for the express terms of this Agreement, Consultant (on behalf
of itself and its employees) hereby expressly declines to participate in such Company employee benefits.

 

(c) Withholding;
Indemnification. Consultant shall have full responsibility for applicable withholding taxes for all compensation paid to
Consultant under this Agreement, and for compliance with all applicable labor and employment requirements with respect to Consultant’s
self-employment, sole proprietorship or other form of business organization, including state worker’s compensation insurance
coverage requirements and any U.S. immigration visa requirements. Consultant agrees to indemnify, defend and hold the Company harmless
from any liability for, or assessment of, any claims or penalties with respect to such withholding taxes, labor or employment requirements,
including any liability for, or assessment of, withholding taxes imposed on the Company by the relevant taxing authorities with
respect to any compensation paid to Consultant.

 

7. Supervision
of Consultant’s Services. All of the services to be performed by Consultant, including, but
not limited to, the Services, will be as agreed between Consultant and the Company’s Officers or their designees. Consultant
will be required to report to the Company’s Officers and any designees concerning the Services performed under this Agreement.
The nature and frequency of these reports will be left to the discretion of the Officers.

 

8. Conflicts
with this Agreement. Consultant represents and warrants that he/she is not under any pre-existing obligation in
conflict or in any way inconsistent with the provisions of this Agreement. Consultant represents and warrants that
Consultant’s performance of all the terms of this Agreement will not breach any agreement to keep in confidence
proprietary information acquired by Consultant in confidence or in trust prior to commencement of this Agreement. Consultant
warrants that Consultant has the right to disclose and/or or use all ideas, processes, techniques and other information, if
any, which Consultant has gained from third parties, and which Consultant discloses to the Company or uses in the course of
performance of this Agreement, without liability to such third parties. Notwithstanding the foregoing, Consultant agrees that
Consultant shall not bundle with or incorporate into any deliveries provided to the Company herewith any third party
products, ideas, processes, or other techniques, without the express, written prior approval of the Company. Consultant
represents and warrants that Consultant has not granted and will not grant any rights or licenses to any intellectual
property or technology that would conflict with Consultant’s obligations under this Agreement. Consultant will not
knowingly infringe upon any copyright, patent, trade secret or other property right of any former client, employer or third
party in the performance of the Services.

 

9. Confidentiality
Agreement. Consultant acknowledges and agrees that concurrently with the execution of this Agreement, he/she
will execute the Confidentiality, Intellectual Property Assignment and Restricted Activities Agreement attached hereto as Exhibit
C (the “Confidentiality Agreement”), and
agrees that all Consultant’s services performed on behalf of the Company will be conducted in accordance with and
governed by the terms of the Confidentiality Agreement.

 

10. Miscellaneous.

 

(a) Amendments and Waivers.
Any term of this Agreement may be amended or waived only with the written consent of the Company.

 

(b) Sole Agreement. This Agreement,
including the Exhibits hereto, constitutes the sole agreement of the parties and supersedes all oral negotiations and prior writings
with respect to the subject matter hereof.

 

    2 

     

    

 

(c) Notices.
Any notice required or permitted by this Agreement shall be in writing and shall be deemed sufficient upon delivery, when delivered
personally or by overnight courier or sent by email or fax (upon customary confirmation of receipt), or forty-eight (48) hours
after being deposited in the U.S. mail as certified or registered mail with postage prepaid, addressed to the party to be notified
at such party’s address or fax number as set forth on the signature page or as subsequently modified by written notice.

 

(d) Choice of
Law. The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the
State of California, without giving effect to the principles of conflict of laws.

 

(e) Severability.
If one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree to renegotiate
such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such
provision, then (i) such provision shall be excluded from this Agreement, (ii) the balance of the Agreement shall be interpreted
as if such provision were so excluded and (iii) the balance of the Agreement shall be enforceable in accordance with its terms.

 

(f) Counterparts.
This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together will constitute
one and the same instrument. Executed copies of the signature pages of this Agreement sent by facsimile or transmitted electronically
in either Tagged Image Format Files or Portable Document Format shall be treated as originals, fully binding and with full legal
force and effect, and the parties waive any rights they may have to object to such treatment.

 

The parties have executed this Agreement as of the Effective
Date.

 

	THE COMPANY:	 
	 	 
	MyDx, Inc., a Nevada corporation	 
	 	 	 
	By:	/s/ Daniel Yazbeck	 
	 	Daniel Yazbeck, CEO	 

 

Address:

6335 Ferris Square, Suite B

San Diego, CA 92121

Attn: Daniel Yazbeck, CEO

Email: daniel@mydxlife.com

 

	CONSULTANT:	 
	 	 
	Mr. Cannabis Inc., a California corporation	 
	 	 	 
	By:	/s/ Erai Beckmann	 
	 	Erai Beckmann, President	 

 

Address:

8008 Girard Street

La Jolla, CA 92037

Attn: Erai Beckmann, President

Email: info@mrcannabis.com

 

    3 

     

    

 

EXHIBIT A

 

DESCRIPTION OF CONSULTING SERVICES

 

Consultant with its affiliate, Mr. Matthew Bucciero, who will
be appointed as the new CEO of the Company, including its subsidiary, CDx, Inc., will successfully transition all current operational
roles referenced below that Mr. Daniel Yazbeck is currently managing. Consultant’s team will accomplish this through the
appointment of existing Mr. Cannabis team members, management of existing MyDx team members and recruitment and new hires.

 

		1.	Chief Executive Officer (CEO) - Manage all Corporate
Communications to engage all stakeholders in the vision of the company. This will include, but is not limited to, writing and
issuance of press releases, general consumer related communications for current and new product releases, vendor and partner communications
and investor/debtors/shareholder communications.

 

		2.	Chief Financial Officer (CFO) - Manage the successful
on time submission of quarterly and yearly financial SEC required filings. Manage monthly cashflow, vendor and employee payments,
creditors and other financial obligations, and financial modelling.

 

		3.	Product and Technology Development (CTO) - Manage
all technical and manufacturing teams to commercialize the production of the EcosmartPen. Manage CannaDx next gen development.
Manage MyDx360 and MyDx Biopharma programs. Manage new product and services development programs.

 

		4.	Marketing (CMO) - Manage, Refine and Grow the MyDx
Brand. This includes, but is not limited to, all marketing and brand updates to existing and future marketing assets including
MyDx Website, MyDx Social Media Platforms, Email marketing database.

 

		5.	Operations (COO) - Manage all corporate and ongoing
operational engagements including vendors, manufacturing partners, and operational staff. Manage Nicholas Hadler (VP Operations)
and address any other gaps in operational services. Prepare for EcoSmartPen Launch with supply chain management, customer service,
marketing, sales, and fulfillment teams to be trained.

 

		6.	Revenue (CRO) - Manage the sales and revenue generating
activities of the Company for existing product lines including CannaDx, MyDx360 and the EcoSmartPen as well as future product
lines. Manage new business development activities for future products and services.

 

		7.	Executive and Advisory Board Management. Manage
and grow existing advisory board to leverage their strengths in achieving Company goals. Schedule and report to the Board of Directors
of MyDx the quarterly progress report of the Company and future plans, with at least 1 quarterly meeting scheduled.

 

    4 

     

    

 

EXHIBIT B

 

COMPENSATION

 

In consideration for the Services and pursuant to the terms
of the Common Stock Purchase Warrant dated as of the Effective Date to be executed by the parties and attached hereto as Exhibit
D (the “Warrant Agreement”), Consultant
shall be issued warrants at the times outlined below and in the Warrant Agreement at or before the
Expiration Date (as defined in the Warrant Agreement), but not thereafter, to subscribe for, purchase and receive twenty two and
one half percent (22.5%) of the common shares issued and outstanding at the time of first notice of exercise given by the Holder,
of the fully paid and non-assessable shares of common stock of the Company (collectively, the “Shares”).

 

For so long as the holder of the Warrant is Consultant and the
Consulting Agreement between Consultant and the Company has not been terminated, Consultant shall have the right to exercise the
warrants pursuant to the Warrant Agreement as follows:

 

		●	Helping to complete the following milestones below, with
such completion to be in the sole judgment of the majority of the members of the Company’s Board of Directors (the “Board”)
, will accelerate the exercise schedule based on the percentage outlined below, with the remainder of the 22.5% equity to remain
on the traditional exercise schedule of 1/36th per month for the remainder of 36 months from the Effective Date.

 

		●	Once the Company has raised capital (with the necessary
amount of such raise to be in the sole judgment of the majority of the members of the Board) the Board will appropriate salaries
to Matt Bucciero and Consultant.

 

		●	Erai Beckmann will be appointed to the Board. Daniel Yazbeck
will remain on the Board as its Chairman.

 

Warrant Exercise Milestones (% Accelerated Vesting):

 

		1.	Complete fundraising of $1,000,000.00 USD or more of capital
for the Company in one or more closings excluding milestone I below. – Immediate right to exercise 5% of the Shares or
a pro rata proportion of the 5% based on the amount of money raised with each closing

 

		2.	Complete fundraising of $5,000,000.00 USD or more of capital
for the Company in one or more closings, at which time 50% of the series A super voting shares will be assigned to Consultant
- Immediate right to exercise an additional 5% of the Shares or a pro rata proportion of the 5% based on the amount of money
raised with each closing

 

		3.	Complete fundraising of $10,000,000.00 USD or more of growth
capital for the Company in one or more closings - Immediate right to exercise 100% of the Shares

 

		4.	Upon achievement of $1,000,000.00 in gross annualized revenue
for MyDx or an increase of market value of a 2x or greater sustained for a minimum of two full weeks or 10 market trading days
- Immediate right to exercise an additional 5% of the Shares

 

		5.	Complete the Reverse Split for the Company’s OTC
Stock at a $2-$4 per share market price and a closing share price of $1 or more for at least a period of 30 consecutive days -
Immediate right to exercise an additional 5% of the Shares

 

    5 

     

    

 

		6.	Complete a cross listing process of the Company stock into
a Canadian or other Foreign exchange - Immediate right to exercise an additional 5% of the Shares

 

Immediate right to exercise an additional 1% of the Shares
shall apply for each the following milestones (A-J):

 

		A.	Complete the successful transition of the management and
the full time operations of MyDx from Mr. Daniel Yazbeck to the Mr. Cannabis Team, marked by the signing of an agreement and announcement
to the public markets via a press release.

 

		B.	Launch the EcoSmartPen with the MyDx Brand to fulfill the
pre-existing orders.

 

		C.	Launch the EcoSmartPen with the Mr. Cannabis brand.

 

		D.	Launch the EcoSmartPen with a reputable brand (in the sole
judgment of the majority of the members of the Board) that has at least $500,000.00 in existing gross sales annualized revenue.

 

		E.	Onboard a major influencer (in the sole judgment of the
majority of the members of the Board)who agrees to help promote the MyDx brand, products and services.

 

		F.	Recruit a reputable head (in the sole judgment of the majority
of the members of the Board)of the scientific board of advisors for MyDx who can work with the MyDx team to unlock the potential
value of the MyDx current and future Database and optimize it to address the needs of the pharmaceutical industry.

 

		G.	Recruit a head of the mobile application development for
MyDx.

 

		H.	Complete an updated diligence packet of materials for MyDx
fundraising, including new and updated financial modelling, new investors presentation, and a well organized (in the sole judgment
of the majority of the members of the Board) cloud based investors diligence folder with all needed fundraising materials/information.

 

		I.	Secure a credit line for MyDx in excess of $3,000,000.00
with a discount to market of no more than 20%.

 

		J.	Recruit and onboard a reputable (in the sole judgment of
the majority of the members of the Board) investors relations team to help ensure the success of the MyDx stock.

 

    6 

     

    

 

EXHIBIT C

 

CONSULTANT CONFIDENTIALITY, INTELLECTUAL
PROPERTY ASSIGNMENT AND RESTRICTED ACTIVITIES AGREEMENT

 

    7Exhibit 10.2

 

SETTLEMENT
AGREEMENT AND GENERAL RELEASE

 

THIS SETTLEMENT AGREEMENT AND GENERAL RELEASE (this
“Agreement”), dated November 10, 2018 (the “Effective Date”), is executed by and between
CDx, Inc., a Delaware corporation and a wholly owned subsidiary of MyDx, Inc., a Nevada corporation, (the “Company”),
and Daniel R. Yazbeck (“Yazbeck”). The Company and Yazbeck are each respectively referred to herein as a “Party”
and collectively as “the Parties.”

 

WHEREAS, at all times hereinafter
mentioned, Yazbeck was and remains the Chief Executive Officer, Chief Financial Officer and Chairman of the Board of Directors
for the Company;

 

WHEREAS, on October 15, 2014, the
Company and Yazbeck entered into an employment agreement (the “Employment Agreement”) for the initial term of
five (5) years whereby Yazbeck was to serve as the Company’s Chief Executive Officer in exchange for the initial base salary
is $180,000 per year;

 

WHEREAS, as of September 30, 2018,
the Company accrued certain base salary and bonus obligations due and owing to Yazbeck as wages, with said wages remaining unpaid
and/or deferred in an amount not less than $410,689.99, as represented on Schedule 1 attached hereto;

 

WHEREAS, Yazbeck was issued a Warrant
on January 3, 2017 in the amount fifteen percent (15%) of the Company’s common stock, at an exercise price of $0.001 per
share (the “Warrant”), as referenced in the Form 8-K filed on January 11, 2017.

 

WHEREAS, in lieu of receiving immediate
cash compensation for the base salary monies due and owing to Yazbeck from the Company upon termination of his Employment Agreement
effective November 10, 2018, Yazbeck has agreed to grant the company an extension to repay this obligation in exchange for the
company reissuing and extending the Warrant currently owned by Yazbeck;

 

NOW, THEREFORE, in consideration
of the mutual covenants and conditions contained herein, and for other good and valuable consideration, the sufficiency and receipt
of which is hereby acknowledged, it is stipulated and agreed, by and among the undersigned, that any default claims arising from
the base salary and bonus compensation detailed in Schedule A that remains due and owing to Yazbeck from the Company under the
Employment Agreement (the “Settled Claims”) are fully and finally settled upon the following terms and conditions:

 

Section 1. Settlement. In exchange
for Yazbeck’s extension of the due date of Settled Claims, with the due date for settled claims now set to January 1, 2020,
the Company shall authorize the termination date extension and reissuance to Yazbeck or his affiliate, YCIG, Inc., of the Warrant
issued on January 3, 2017 in the amount fifteen percent (15%) of the Company’s common stock, at an exercise price of $0.001
per share (the “Warrant”), in the updated form attached hereto as Exhibit A  (the “Settlement”);
The approval and issuance of the Settlement shall be made within a reasonable time subsequent to the Effective Date, but in no
case later than the due date of the Company’s next periodic filing on Form 10-Q.

 

     

     

    

 

Section 2. Default. In the event
that the Company defaults in the performance of its obligations to approve and issue the Settlement Amount and such default continues,
following notice, for a period of ten (10) business days (“Cure Period”), then an amount equal to the total
of accrued wages/liabilities related to Yazbeck, as listed on Schedule 1, (less any payments or share issuances received by Yazbeck
pursuant to the terms of this Agreement or otherwise) shall immediately become due and payable as liquidated damages to Yazbeck
or his affiliate, YCIG, Inc.

 

Section 3. Release by Yazbeck. Upon
execution of this Agreement, Yazbeck, on his own behalf, and on behalf of his respective past, present or future parent entities,
divisions, affiliates, subsidiaries, related business entities, shareholders, members, partners, limited partners, present and
former directors, managing directors, managers, officers, control persons, shareholders, employees, agents, attorneys, administrators,
heirs, executors, trustees, beneficiaries, representatives, successors and assigns (collectively, the “Yazbeck Releasing
Parties”), hereby absolutely, unconditionally and irrevocably RELEASE and FOREVER DISCHARGE the Company, its subsidiaries,
and each of its respective past, present or future parent entities, divisions, affiliates, subsidiaries, related business entities,
shareholders, members, partners, limited partners, directors, managing directors, managers, officers, control persons, employees,
agents, attorneys, administrators, representatives, successors and assigns (collectively, the “Company Released Parties”)
from any and all claims, actions, causes of action, suits, accounts, covenants, contracts, controversies, agreements, promises,
damages, judgments, executions, claims and demands, whether known or unknown, suspected or unsuspected, absolute or contingent,
direct or indirect or nominally or beneficially possessed or claimed by any of the Yazbeck Releasing Parties, whether the same
be at law, in equity or mixed, which such Yazbeck Releasing Party ever had, now has, or hereafter can, shall or may have against
any or all of the Company Released Parties, in respect of or arising from the Settled Claims, (collectively the “Yazbeck
Released Claims”); provided, however, that nothing contained in this Agreement shall be construed to prohibit Yazbeck
from bringing appropriate proceedings to enforce the obligations of the Company set forth under Section 1 or to fulfill its obligations
hereunder, none of which are released hereby until Yazbeck’s receipt of the Settlement Amount.

 

Section 5. Release
by the Company. Upon the execution of this Agreement, the Company, on its own behalf, and on behalf of its respective past,
present or future parent entities, divisions, affiliates, subsidiaries, related business entities, shareholders, members, partners,
limited partners, present and former directors, managing directors, managers, officers, control persons, shareholders, employees,
agents, attorneys, administrators, heirs, executors, trustees, beneficiaries, representatives, successors and assigns (collectively,
the “Company Releasing Parties”), hereby absolutely, unconditionally and irrevocably RELEASE and FOREVER DISCHARGE
each of Yazbeck, his respective affiliates and each of his respective past, present or future entities, divisions, affiliates,
subsidiaries, related business entities, shareholders, members, partners, limited partners, directors, managing directors, managers,
officers, control persons, employees, independent contractors, agents, attorneys, administrators, representatives, successors
and assigns (collectively, the “Yazbeck Released Parties”) from any and all claims, actions, causes of action,
suits, debts, liabilities, obligations, sums of money, accounts, covenants, contracts, controversies, agreements, promises, damages,
judgments, executions, claims and demands, whether known or unknown, suspected or unsuspected, absolute or contingent, direct
or indirect or nominally or beneficially possessed or claimed by any of the Company Releasing Parties, whether the same be at
law, in equity or mixed, which such Company Releasing Party ever had, now has, or hereafter can, shall or may have against any
or all of the Yazbeck Released Parties, in respect of or arising from the Settled Claims, (collectively the “Company
Released Claims” and together with the Yazbeck Released Claims, the “Released Claims”); provided, however,
that nothing contained in this Agreement shall be construed to prohibit the Company from bringing appropriate proceedings to enforce
the obligations of Yazbeck hereunder, none of which are released hereby until Yazbeck’s receipt of the Settlement Amount.

 

    	 	- 2 -	 

     

    

 

Section 6. No Suits or Actions.
Except as provided for herein with respect to the Company’s failure to timely pay the Settlement Amount, each of the Releasing
Parties hereby irrevocably covenants to refrain from asserting any claim or demand, or commencing, instituting or causing to be
commenced, any proceeding of any kind against any Yazbeck Released Party (in such capacity, each a “Released Party”),
as applicable, based upon any Party’s Released Claim. If any of the Releasing Parties brings any claim, suit, action or manner
of action against the Released Parties (or any of them) in administrative proceedings, in arbitration, at law, in equity, or mixed,
with respect to any Released Claim, then such Releasing Party shall indemnify the Released Parties (or any of them) in the amount
or value of any final judgment or settlement (monetary or other) and any related cost (including without limitation reasonable
legal fees) entered against, paid or incurred by the Released Parties (or any of them).

 

Section 7. Power, Authority and Capacity.
Each Party represents and warrants to the other Party that it has the power, authority and capacity to enter into this Agreement.

 

Section 8. Preparation of Agreement.
Each Party represents to the other that its counsel have negotiated and participated in the drafting of, and are legally authorized
to negotiate and draft, this Agreement. Each Party to this Agreement acknowledges that this Agreement was drafted jointly by the
Parties hereto and each Party has contributed substantially and materially to the preparation of this Agreement. The Agreement
shall be construed as having been made and entered into as the result of arms-length negotiations, entered into freely and without
coercion or duress, between parties of equal bargaining power. The language in this Agreement and any documents executed in connection
therewith shall be interpreted as to its fair meaning and not strictly for or against any Party.

 

Section 9. No Assignment of Released
Claims. Each Releasing Party represents and warrants to the Released Parties that there has been no assignment or other transfer
of any interest in any Released Claim.

 

Section 10. Severability. If any
provision of this Agreement is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this
Agreement will remain in full force and effect. Any provision of this Agreement held invalid or unenforceable only in part of degree
will remain in full force and effect to the extent not held invalid or unenforceable.

 

    	 	- 3 -	 

     

    

 

Section 11. Amendment; Governing Law.
This Agreement may not be amended, modified or supplemented except in a writing signed by the Parties. This Agreement shall be
governed by and construed under the laws of the State of New York without regard to principles of conflicts of law.

 

Section 12. Counterparts. This Agreement
may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

 

Section 13. Waiver. No delay in
exercising any right hereunder shall be deemed a waiver thereof, and no waiver shall be deemed to have any application to any future
default or exercise of rights hereunder.

 

Section 14. Entire Agreement. This
Agreement constitutes the entire agreement between the Parties hereto with respect to the subject matter hereof and may be amended
only by a writing executed by all Parties hereto. No Party has relied on any representations not contained within or referred to
in this Agreement and the documents delivered herewith.

 

Section 15. Captions. The captions
of the various sections and paragraphs of this Agreement have been inserted only for the purposes of convenience; such captions
are not a part of this Agreement and shall not be deemed in any manner to modify, explain, enlarge or restrict any of the provisions
of this Agreement.

 

[SIGNATURE PAGE FOLLOWS]

 

    	 	- 4 -	 

     

    

 

IN WITNESS WHEREOF, the Parties
have executed this Agreement effective as of the date first above written.

 

	 	CDx, Inc.
	 	 	 
	Date: Nov 10, 2018	By:	/s/ Matt Bucciero
	 	Name: 	Matt Bucciero
	 	Title:	Chief Executive Officer

 

	 	MyDx, Inc.
	 	 	 
	Date: Nov 10, 2018	By:	/s/ Matt Bucciero
	 	Name: 	Matt Bucciero
	 	Title: 	Chief Executive Officer

 

	Date: Nov 10, 2018	/s/ Daniel R. Yazbeck
	 	Daniel R. Yazbeck

 

    	 	- 5 -	 

     

    

 

SCHEDULE 1

 

CDx, Inc. Accrued Liabilities –
Accrued Wages/Compensation Due to Yazbeck

 

Accrued Wages: As of 9/30/2018: $410,689.99

 

	Daniel Yazbeck	 	 	 	 	9/30/2018	 
	 	 	 	 	 	 	 
	 	 	Accrue wages @

9/30/2018	 	 	410,689.99	 
	 	 	 	 	 	 	 
	Daniel Yazbeck	 	total	 	 	410,689.99	 

 

    	 	- 6 -	 

     

    

 

EXHIBIT A

 

WARRANT D1

 

(See attached).

 

    	 	- 7 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}]]